DW

Daniel White

Chief Executive Officer & Director

Lanier Biotherapeutics

Lanier Biotherapeutics Pipeline

DrugIndicationPhase
Checkpoint Inhibitor Pneumonitis (CIP) ProgramCheckpoint Inhibitor PneumonitisPre-clinical
Type 2 Inflammation / Fibrosis ProgramAsthma, Atopic Dermatitis, Chronic Rhinosinusitis with Nasal Polyps, Eosinophilic Esophagitis, Food AllergiesPre-clinical
Retinal ProgramRetinal diseases (e.g., Age-related Macular Degeneration)Pre-clinical